The ability of complement to inactivate human immunodeficiency virus (HIV) in the presence of specific antibody was evaluated. HIV was treated with complement and/or antibody, and then its titer was determined on the CD4+ H9 cell line. While complement alone had no effect on the HIV titer, complement plus subneutralizing levels of antibody resulted in titer reductions. Complement sources deficient in membrane attack component C5 or C8 did not inactivate antibody-treated HIV, suggesting that neutralization occurred via lysis. This possibility was investigated by assessing release of reverse transcriptase (RT) from the virion. Antibody plus complement, but neither reagent alone, released RT from HIV in a dose-dependent manner. Release of RT did not occur with C5-or C8-deficient sera, also indicating a requirement for membrane attack components. These studies show that complement can neutralize HIV via the classical complement pathway and that this neutralization occurs via C5b-9-mediated viral lysis. Thus, complement may play a major role in resistance to disease by lysing HIV and preventing infection of Fc-and complement receptor-positive cells, as well as CD4+ cells.
The complement system can neutralize viruses by several mechanisms (7, 12) . Virus-specific antibody can activate either the classical or alternative complement pathway. Antibody-independent activation of the alternative pathway can also occur. Some animal retroviruses have been found to activate the classical complement pathway without antibody by direct binding of Clq to viral proteins, resulting in virus destruction (2, 6, 27) . However, the human retroviruses human immunodeficiency virus (HIV) (1) and human T-cell lymphotropic virus type I (HTLV-I) (1, 15) are not destroyed by complement in this manner.
The ability of complement to neutralize HIV in the presence of specific antibody has not been reported. Complement, if activated by antibody, can neutralize viruses by at least two mechanisms, i.e., direct lysis and physical interference with infection by deposition of complement proteins on the virus surface (12) . Evaluation of potential HIV neutralization by antibody and complement is important in view of reports that antibody or complement may actually, under some conditions, mediate or enhance the ability of HIV to infect cells that bear Fc or complement receptors (11, 14, 19, 22, 23, 25) . Thus, if complement does not lyse HIV in the presence of antibody, even in the presence of antibody capable of neutralizing infection of CD4+ cells, the virus could remain infectious for both complement receptor-and Fc receptor-positive cells.
The goal of this study was to determine whether complement can inactivate HIV in the presence of antibody. Complement-mediated neutralization was found, and the mechanism by which it occurred was investigated.
MATERIALS AND METHODS
Cell and virus culture. The H9 T-cell line was used to propagate the HTLV-IIIRF strain of HIV (21 RT assay. Incubation of virus with complement and antibody to measure RT release was done essentially as described above, except that the final incubation volume was 60 ,ul and pooled sera (RT absorbed) were used at a 1:12 final dilution. The RT assay is an adaption (28) of a previously described method (10) . Briefly, 10 IlI of culture supernatant was mixed with 50 ,ul of an RT reaction mixture containing a template primer of (A), (5 Rg/ml) and (dT)12_18 (1.57 jig/ml) (both from Pharmacia LKB Biotechnology, Piscataway, N.J.) in 50 mM Tris (pH 7.8)-7.5 mM KCI-2 mM dithiothreitol-5 mM MgCl2-0.5 ,uCi of [32P]dTTP (400 Ci/mmol). To determine the detergent-releasable counts, the above-described buffer was made to contain 0.05% Nonidet P-40. Following incubation for 90 min at 37°C, 10 (1) have demonstrated that complement alone has no effect on HIV. In the present study, the infectivities of two HIV isolates, HTLV-IIIRF and HIV76, were unchanged by treatment with complement, confirming the results of Banapour et al. (1) (Fig. 1 ; data not shown).
Since essentially all infected patients develop antibody to HIV, the combination of antiserum plus complement was tested for the ability to neutralize HIV. Pooled sera used as a source of anti-HIV antibody was HI to destroy complement activity and diluted to have a low neutralizing effect. When virus was treated with pooled sera alone, a low level of neutralization was observed (Fig. 1) . In contrast, addition of complement, at final dilutions of 1:3 and 1:12, to pooled sera resulted in significant decreases in HIV titer (Fig. 1) . While some HIV neutralization was noted with complement at a final dilution of 1:48 plus antibody, it was not significantly greater than that observed with antibody treatment alone. Complement treatment alone did not significantly affect HIV titer (Fig. 1) . The ability of complement at a dilution of 1:12 to neutralize two virus isolates in combination with pooled sera or antiserum from one person was tested. Complement plus antibody (pooled or antibody from patient 76) reduced HTLV-IIIRF titers by an average of 88% compared with antibody treatment alone (Fig. 2) . Complement plus antiserum from patient 76 reduced H1V76 titers by 80% over antibody treatment alone, while complement and pooled antisera reduced H1V76 titers by 47% over treatment with pooled antisera alone (Fig. 2) . In two of the experiments shown in Fig. 2 sufficient for neutralization (8, 17) . While pooled sera along with normal complement neutralized HIV, no neutralization with C5-depleted or C8-deficient complement was detected (Table 1 ). These results indicated that the terminal attack components of complement were necessary for neutralization, which in turn suggests that neutralization was due to lysis of HIV virions.
Release of RT by antibody and complement. Intact virions do not express RT activity until the virus envelope is disrupted. If complement-and-antibody treatment results in virion lysis, RT activity should be released, as with animal retroviruses (2, 6, 27) . Initial experiments to detect RT release demonstrated a complicating factor; i.e., sera from HIV-infected persons contained anti-RT antibody which inhibited detection of RT (data not shown), as also reported by others (16) . To avoid this problem, the anti-RT antibody was removed from sera by passage over an RT affinity column before use. No RT-inhibitory activity was detected in the resulting antisera (data not shown).
Incubation of HTLV-IIIRF with antibody plus complement at dilutions of 1:3 to 1:27 resulted in release of RT (Fig.  3) , while antibody plus complement at higher dilutions (1:81 and 1:243) did not result in measurable RT release. In contrast, treatment of virus with complement alone or antibody alone did not result in detectable release of RT (Fig. 3) .
The ability of complement to release RT from diverse isolates of HIV was also evaluated. Pooled antibody in conjunction with complement released RT from HTLV- "'MN and HIV76 in addition to HTLV-IIIRF, while complement or antibody alone did not induce release ( Table 2) .
The mechanism by which complement released RT was also assessed by using sources of complement deficient in or depleted of one complement component. While fully active complement and antibody induced RT release, sera deficient in C2 did not, indicating that RT release was induced by the classical pathway (Table 3) . As in the neutralization experiments, sera deficient in C5 or C8 were not able to cause RT release ( Table 3) . Mixing of the deficient sera restored RT-releasing activity (Table 3) . In two experiments, addition of subphysiologic, limiting amounts of highly purified C2, CS, or C8 to the appropriate deficient sera also partially restored RT-releasing activity (8.8, 5.9, and 6.2% specific RT release, respectively; data not shown).
DISCUSSION
This study shows that complement combined with antibody can inactivate HIV. The requirement for antibody, together with the observation that C2-deficient serum plus antibody does not release RT, indicates that HIV neutralization occurred by the classical complement pathway. This mechanism of neutralization is similar to that shown for many other enveloped viruses (12) .
This study also provides evidence that the mechanism of neutralization is viral lysis by showing that the membrane attack complex of complement is required and that RT is released during incubation with complement. Some animal retroviruses have also been shown to be susceptible to complement-mediated lysis and neutralization, although the mechanism of complement activation was antibody independent (2, 6, 27) . The human HTLV-I retrovirus has been shown by Hoshino et al. (15) to be resistant to lysis by complement with or without the presence of anti-HTLV-I antibody. Thus, the current study is the first description of susceptibility of a human retrovirus to complement-mediated lysis.
Many recent studies have shown that immunoglobulin G-coated HIV can infect cells after binding to Fc receptors (14, 19, 25 (Fig. 3) . Therefore, it seems likely that at higher concentrations of complement, complement-mediated enhancement of HIV infection may disappear because of neutralization. Preliminary experiments performed in this laboratory support this contention (G.T.S., unpublished data).
This study suggests that complement in conjunction with antibody in the blood of HIV-infected individuals may lyse HIV and destroy infectivity. However, the presence of infectious virus in plasma from HIV-infected persons has been reported (5, 9, 13). Virus titers were found to be 10-fold (5) to 100-fold (13) higher in symptomatic persons than in asymptomatic persons. There are several possible mechanisms by which plasma virus could escape complement lysis. Infectious virus found in plasma may be resistant to complement lysis because of low levels of complement components during infection. Significant depletion of classical pathway components and increases in complement activation products have, in fact, been reported in patients with acquired immunodeficiency syndrome (18, 20, 26) . This activation and depletion may be, to a large extent, due to antibody complexed to HIV or HIV antigens (4). Alternatively, virus present in plasma could represent complementresistant virus due to mutated envelope proteins. Thus, complement-activating anti-HIV antibodies present in plasma may be unable to bind to, and thus lyse, HIV isolates from plasma of the same individual. The virus found in plasma may, however, represent complement-sensitive virus that was recently released by cells and which is in the process of being lysed. In fact, free HIV antigen which may represent lysed HIV is found in these patients (5, 13) .
Further studies in which the sensitivities of virus from plasma and other viral isolates to complement lysis are compared and which attempt to correlate complement levels and viremia are needed.
In conclusion, the results of this study show that complement can have significant effects on HIV infectivity. These findings emphasize the importance of considering the contribution of complement to HIV neutralization in studies which address HIV-antibody interaction.
